Alloy Therapeutics, Inc. Announces Executive Appointments

Alloy Therapeutics announced the appointment of Michael Schmidt, as Chief Scientific Officer (CSO) and the promotion of Martin Leach,to Chief Operating Officer (COO).

Michael Schmidt, most recently served as CSO at Ankyra Therapeutics. In this role, he will be responsible for technical innovation and ensuring scientific excellence across Alloy’s platforms, services, and venture studio.

Martin Leach, previously held the position of Alloy Senior Vice President of Global Informatics and COO of the Daedamab research facility.
Alloy Therapeutics is a leading company in drug discovery capabilities and technologies.